Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report

	Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report
刊名	FRONTIERS OF MEDICINE
	2018
卷号	12
关键词	BCL-2 INHIBITOR MIDOSTAURIN CLASSIFICATION DECITABINE MECHANISMS MUTATIONS TARGETS IDH BTK venetoclax cytarabine AML leukemia
ISSN号	2095-0217
其他题名	Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report
英文摘要	Conventional combination therapies have not resulted in considerable progress in the treatment of acute myeloid leukemia (AML). Elderly patients with AML and poor risk factors have grave prognosis. Midostaurin has been recently approved for the treatment of FLT-3-mutated AML. Venetoclax, a BCL-2 inhibitor, has been approved for the treatment of relapsed and/or refractory chronic lymphoid leukemia. Clinical trials on applying venetoclax in combination with cytarabine and other agents to treat various hematological malignancies are currently underway. Here, we present a case of a male patient with poor performance status and who developed AML following allogeneic hematopoietic stem cell transplant for high-risk myelodysplasia. The patient with high risk AML achieved complete response to the combined treatment regimen of low-dose cytarabine and venetoclax. Furthermore, we reviewed current clinical trials on the use of venetoclax for hematological malignancies.
资助项目	[Zhengzhou University Training Grant] ; [National Natural Science Foundation of China] ; [2017 CAHON Young Investigator Award]
语种	英语
CSCD记录号	CSCD:6375350
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/50517]
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report[J]. FRONTIERS OF MEDICINE,2018,12.
APA	(2018).Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.FRONTIERS OF MEDICINE,12.
MLA	"Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report".FRONTIERS OF MEDICINE 12(2018).